title: Reversible neurological deficit after foam sclerotherapy.
abstract: A 37-year-old male was treated with 9 ml of 3% polidocanol foam, and he immediately reported photopsiae lasting a few minutes, though without migraine. Two hours after sclerotherapy, the patient developed speech disturbance for a few minutes. A pathological examination revealed nothing except a patent foramen ovale (PFO). Given the contrast between the high prevalence of PFO in general population and the extremely low incidence of neurological deficits after foam sclerotherapy, these deficits may only arise due to as-yet-unknown aetiology.
authors.affiliation: Hartmann & Partners Phlebology Practice, Zähringerstr. 14, 79108 Freiburg, Germany. kahartmann@web.de
authors.forename: K
authors.initials: K
authors.lastname: Hartmann
authors.forename: L
authors.initials: L
authors.lastname: Harms
authors.forename: M
authors.initials: M
authors.lastname: Simon
mesh_terms: D000328:Adult; D054092:Foramen Ovale, Patent / Q000150:complications / Q000175:diagnosis; D006801:Humans; D008297:Male; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000009:adverse effects*; D012307:Risk Factors; D012597:Sclerosing Solutions / Q000009:adverse effects*; D015911:Sclerotherapy / Q000009:adverse effects*; D013064:Speech Disorders / Q000209:etiology*; D053828:Stockings, Compression; D018616:Ultrasonography, Doppler, Duplex; D018084:Ultrasonography, Interventional / Q000379:methods; D014648:Varicose Veins / Q000000981:diagnostic imaging / Q000628:therapy*; D014786:Vision Disorders / Q000209:etiology*
chemical_list: D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols